ATTR-ACT: Summary
ATTR-CM is a fatal, underrecognized, and underdiagnosed disease1
Tafamidis is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization5
Tafamidis reduced the hierarchical combination of all-cause mortality and frequency of cardiovascular-related hospitalizations in patients with ATTR-CM compared with placebo over 30 months (p=0.0006)1
Tafamidis reduced the decline in functional capacity and health status compared with placebo at Month 30 (p<0.001)1
Tafamidis was well tolerated, with a safety profile comparable to placebo1,5
ATTR-CM: transthyretin amyloid cardiomyopathy.
